USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ATHERSYS, INC.
Address: 3201 CARNEGIE AVE
CLEVELAND, OH 44115-2634
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,427,107.00 11
SBIR Phase II $2,289,623.00 2
STTR Phase I $136,500.00 1
STTR Phase II $617,224.00 1

Award List:

Genome-Wide Growth Factor Discovery in the CNS

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: John J. Harrington
Award Amount: $99,111.00
Abstract:
DESCRIPTION:We propose to carry out a rapid genome-wide search for new mitogens and survival factors for stem and precursor cells of the CNS, potentially doubling or more the number of known CNS mitogenic and survival factors over the course of two years. To do this, a novel… More

Use of Genome-Wide Protein Expression Libraries

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: John J. Harrington
Award Amount: $99,111.00
Abstract:
DESCRIPTION (Applicant's abstract): We propose a novel high-throughput approach to the discovery of novel mitogens. We will use Random Activated Gene Expression (RAGE), which allows unbiased expression of full-length, or near full-length, transcripts of greater than 95… More

Drug Target Discovery in Mast Cells by GECKO Technology

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul D. Jackson
Award Amount: $99,800.00
Abstract:
DESCRIPTION (provided by applicant): The goal of the present research program is to utilize a genome-wide, high-throughput gene knock-out technology in combination with cellular assays to identify anti-inflammatory drug targets. This novel knockout technology, termed Genome-wide Cell-based Knockout… More

Genome-Wide Growth Factor Discovery in the CNS

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: John J. Harrington
Award Amount: $734,404.00
Abstract:
DESCRIPTION (provided by applicant): We propose to carry out a rapid genome-wide search for new mitogens and survival factors for stem and precursor cells of CNS, potentially doubling or more the number of known CNS mitogenic and survival factors over the course of two years. To do this, a novel… More

Genome-Wide Growth Factor Discovery in the CNS

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: John J. Harrington
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): We propose to carry out a rapid genome-wide search for new mitogens and survival factors for stem and precursor cells of CNS, potentially doubling or more the number of known CNS mitogenic and survival factors over the course of two years. To do this, a novel… More

In-vitro generation of cardiomyocytes from MAPC

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Wouter J. Vanthof
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The development and institution of stem cell and tissue engineering methodologies hold the potential to target many of the most significant cardiovascular diseases and have a dramatic impact on the treatment of one of the leading causes of death in the United… More

Development of NFkappaB Inhibitors

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce A. Sherf
Award Amount: $99,990.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this Phase I proposal is to identify novel regulators of transcription factor NFkappaB. The products of this Phase I discovery program will be targets utilized in a Phase II campaign to develop of small molecule inhibitors as potential new drug… More

Autologous cell therapy with SMC modified MAPCs

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: John J. Harrington
Award Amount: $99,850.00
Abstract:
DESCRIPTION (provided by applicant): The objective of the current proposal is to establish genetic modification of Multipotent Adult Progenitor Cells (MAPCs) with Synthetic Microchromosome vectors (SMCs) as a strategy for application in autologous cell based therapy of Hurler's Syndrome… More

Small Molecular Inhibitors of Artemis as Radiosensitizer

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Stephen E. Rundlett
Award Amount: $99,944.00
Abstract:
DESCRIPTION (provided by applicant): Recent advances in our understanding of DNA repair mechanisms have led to the identification of the DNA repair specific nuclease, Artemis. Mutations in this enzyme do not affect viability, but enhance cellular sensitivity to ionizing radiation through the… More

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: MEDICAL COLLEGE OF GEORGIA (MCG)
Principal Investigator: James E. Carroll
Award Amount: $136,500.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The emergence of technologies enabling isolation of adult stem cells has allowed evaluation of cell therapeutics for central nervous system disorders with a path for clinical development. Much promise has been shown using stem cells in acute disease models such… More

Stem Cells for Neonatal Hypoxic-Ischemic Brain Injury

Award Year / Program / Phase: 2007 / STTR / Phase II
Agency: HHS
Research Institution: MEDICAL COLLEGE OF GEORGIA
Principal Investigator: Cesario V. Borlongan
Award Amount: $617,224.00
RI Contact: N/A
Abstract:
DESCRIPTION: The specific objective of this STTR Phase II research and development project is to provide an optimized cellular therapy regimen for treating hypoxic-ischemic (HI) injury and its related outcomes in neonates. Pre- clinical studies performed i n a rat pup model of HI injury as part of… More

Optimization of the angiogenic potential of multipotent adult progenitor cells

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert Deans
Award Amount: $99,302.00
Abstract:
DESCRIPTION (provided by applicant): Peripheral Vascular Disease (PVD) results from chronic loss of the oxygen supply to the lower limbs due to arterial blockage. Loss of oxygen to these tissues can result in pain, ulcers, infection and limb amputation in patients. PVD affects up to 12% of the… More

Cell Based Therapy for Treatment of Traumatic Brain Injury

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert W. Mays – 216-426-3574
Award Amount: $299,999.00
Abstract:
DESCRIPTION (provided by applicant): Previously performed and published studies have demonstrated that MultiStem(R), Athersys' patented adult adherent stem cell product, modulates the inflammatory component of secondary brain injury in rodent models of traumatic brain injury (TBI). Further,… More

Pediatrician Office Drug Prevention

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Anthony Ting – 216-431-9900
Award Amount: $330,000.00
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) represents a significant unmet medical need with over 1 million patients in the United States suffering from acute myocardial infarction (AMI) each year. This epidemic of heart attacks alsorepresents a risk factor for further… More

Cell Based Therapy for Treatment of Traumatic Brain Injury

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Robert W. Mays – 216-426-3574
Award Amount: $1,555,219.00
Abstract:
DESCRIPTION (provided by applicant): Previously performed and published studies have demonstrated that MultiStem(R), Athersys' patented adult adherent stem cell product, modulates the inflammatory component of secondary brain injury in rodent models of traumatic brain injury (TBI). Further,… More